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Summary A correlation analysis was performed on 223 breast carcinomas to assess the relationships between gene amplification,
karyotypic and clinicopathological features. Homogeneously staining region (HSR) is the most frequent form of amplification found in breast
cancer. HSR-containing tumours accounted for 60C% of the cases. Although up to 400/o of tumours with slightly altered karyotype contained
HSRs, an excess of HSRs was found within the tumours whose karyotype showed the highest rates of rearranged chromosomes. HSRs were
also found to be particularty frequent in small tumours of high histological grade and with a low expression of progesterone receptors. An
excess of HSRs seems to be observed in younger patients, however, significant correlation could be demonstrated onty for patients below 55
years and below 60 years, compared with older ones. With a 120-month follow-up for 152 patients, a significant association between the
presence of HSRs and a shortened overall survival was observed. Altogether, the presence of HSRs appears to be a good indicator of poor
prognosis. Further studies are needed to determine whether amplification of specific genes or cell ability to amplify is the most important
parameter for tumour progression.
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Cytocenetic studies and clinicopathological data of breast cancer
have established correlations between chromosome alterations and
histolooical gradinc (Dutrillaux et al 1991: Emerson et al. 1993:
Pandis et al. 1996). proliferative activity (Remvikos et al. 1992)
and steroid hormone receptor status (Magdelenat et al. 1992).
Other studies have also proposed a possible relationship betmeen
prognosis and specific chromosome alterations. such as chromo-
some I rearrangements (Hainsworth et al. 1992) or the presence of
homogeneousl- staining regions (HSRs) (Zafrani et al. 1992).
However. most of these studies considered a limited number of
cases, and their findings rarely reached statistical significance.
As proposed by Gerbault-Seureau et al (1987) and Saint-Ruf et
al (1991). HSRs. as hallmarks of gene amplification. frequently
occur in breast cancer cells. Their relationship with known proto-
oncogene amplifications. such as MYC. ERBB2 and CCNDJ. has
been shown to be complex (Saint-Ruf et al. 1990). and studies
using comparative genomic hNbridization (CGH) have shown that
multiple sites may be the targets of amplifications (Guan et al.
1994: Kallionemi et al. 1994: Muleris et al. 1994a. 1995: Trent
et al. 1995). Thus. in addition to molecular studies (Bi&che and
Lidereau. 1995). it remains of interest to determine wvhether or not
the presence of amplified DNA sequences forming HSRs is
indicative of an adverse prognosis.
The results of a study of 223 priman breast cancers with
kan-otypic alterations are reported. They demonstrate a statistical
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correlation between the presence of HSRs and prognostic factors.
confirming the tendencies obser ed in our preliminary analy sis of
84 ofthese cases (Zafrani et al. 1992).
MATERIAL AND METHODS
Patients
Between 1984 and 1995. a cytogenetic studyvwas successfully
performed on 223 primary breast carcinomas. All patients were
females. with aaes ranging from 15 to 86 years. the mean age
beinga 58 vears. Fourteen patients had been treated with radio-
therapy. chemotherapy or hormonotherapy before surgerv. TNM
staring, of the tumours was performed according to the Union
Intemationale Contre le Cancer (UICC. 1988) (Table 1).
Pathological analysis
All but tuo tumours. histopathologically classified according to
the World Health Organization recommendations. w-ere infiltrating
carcinomas. Ductal and lobular types contributed to 85%'c and 5%
of cases respectively. The remaining cases were classified as
tubular. medullary. mucinous. apocrine. papillary. pseudosarcoma-
tous and undifferentiated carcinomas. Two cases wvere classified as
ductal in situ carcinomas. Histological grading wvas performed
usinc a modification of the criteria defined by Bloom and
Richardson (Elston and Ellis. 1991). Axillar- nodal involvement
was recorded. as wvell as the histopathological size ofthe tumours.
Cytogenetic analysis
Cy togenetic analysis vias performed on fresh tumours after
surgery for most ofthe cases or on drill biopsies in some instances.
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Figure 1 Examples of HSR carrier chromosomes nos. 7.8. 10. 11 12. 17.
19 and 20. The lines along the chronosomes indicate the extent and the
localization of the HSRS. The corresponding normal chromosome is
presented on the left side of the HSR carmer chromosome
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Figure 2 Histograms showing the percentages of the HSR+ (filled bars) and
HSR- (empty bars) tumrours as a function of chromosome number. n. number
of cases
Short-term cultures. metaphase spreading and R-bandingr were
performed as described previously (Gerbault-Seureau et al. 1987).
Chromosomal counts and rate of rearranged chromosomes were
established according to Dutnillaux et al (1991).
Steroid receptor assays
Oestrogen (ER) and progesterone (PR) receptors were measured
as previously described (Magdelenat et al. 1992) using solid phase
immunoenzvmetric assays (ER-EIA and PR-EIA. Abott. USA)
according to the manufacturer's recommendations. Briefly.
tumour tissue samples were homogenized in a 10 m-.t Tris glvcerol
(10% vX) 10 m-M sodium molybdate. I m-tN dithiothreitol buffer
containing 0.4 !I potassium chloride. After centrifugation at
105 000 g (1 h. 4 C). the supematant (cytosol) was used for ER
and PR and total protein assays and the pellet for DNA assay:
receptor status was stratified as follows (Magdelenat et al. 1992):
Table 1 Distribution of patients according to the UICC classification
NO Nla Nib N2 Nx Total
TO 1 0 0 0 0 1
Ti 29 2 7 0 0 38
T2 82 16 20 1 1 120
T3 12 6 6 0 0 24
T4 4 1 4 0 0 9
Total 128 25 37 1 1 192
ER-. PR- if< 500 fmol per g tissue (gt)
ER+. PR+ if > 500 fmol per g, tissue (gt(
The receptor status sas available for 193 tumours.
Statistical analysis
Correlations betw-een variables were tested using the X test.
Sur-vival curves were draw-n using the Kaplan-Meier method
(Kaplan and Meier. 1958) and compared with the log-rank test.
RESULTS
The presence of one HSR or more per metaphase w-as detected in
129 out of 223 (58%c) tumours. As a rule. HSRs were present
(HSR+) or absent (HSR-) in all metaphases from the same tumour.
Among the 14 tumours treated by radio- or chemotherapy before
surgery. eight had HSRs. a proportion (57%-,r) similar to that ofnon-
treated tumours. In HSR+ tumours. the number of HSRs per cell
varied from one to five. but was fairlv constant in a airven tumour.
DNA amplification was checked by CGH in 28 out of 129 cases of
this study. Positive signals were obserxed in 27 tumours (Mulen's
et al. 1994a. 1995: Bemardino et al. 1998). In one of the twso
remaining cases. ERBB2 gene amplification could be demon-
strated by fluorescence in situ hNbridization (FISH). Thus. the
classical R-banding used in this studv is assumed to be relevant for
DNA amplification detection in HSRs. Examples of HSR carrier
chromosomes are shown in Figure 1.
Representativeness of our series
The mean age of the patients in our study (58 years) was slightly
higher than that of the large reference series of our institute (56
years).
TNM staging of the tumours w-as also compared w-ith the refer-
ence series. In this series. 0.5%7. 15%. 48%T. 25%7c and 11.5%7c were
classified as stage 0. I. Ia. Ilb and MIl respectively. while in the
reference series these percentages were of 5.5%7c. 29.5%-. 30%.
23.5%7 and 11.5% respectively. These differences were due to the
low availabilitv of stage 0 or I tumours for cvtogenetic studies
because of small tumour sizes.
Correlations between the presence of HSRs and other
cytogenetic features
As proposed. breast cancer cells that have undergaone an
endoreduplication can further evolve by chromosome losses and
rearrangements. decreasing their chromosome numbers to about
50 (Dutrillaux et al. 1991). Taking, this criterion to define the
ploidy. 111 tumours were non-polyploid (near-diploid or
hypodiploid) (< 50 chromosomes) and 112 were polvploid (> 50
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Table 2 Relationship between clinicopathliogical parameters and presence
of HSRs in the tunours using the X2 test comparing subsampJes a-s. For ER
and PR. the observed values were compared with that of a theoretical
distribution of HSR at random. P-values < 0.05 were considered significant
No. of HSR+ tumours P-value
patients no. (%)
Patient age (years)
<40 21 13 (62) a a/b: NS
>40 202 116 (57.4) b
<50 79 49 (62) c cld: NS
>50 144 80 (55.5) d
.55 101 66 (66) e e/t 0.04
>55 122 63 (52) f
.60 123 79 (64)g 9 h: 0.03
>60 100 50 (50) h
Tumour size (mm)'
.20 68 47 (69)i ifj+k+l: 0.01
.30 83 44 (53) j ij+kA: 0.02
<40 31 17 (55) k LAykA: 0.06
>40 33 14(42.5)1
Histological grade"
1 23 6 (26) m
2 101 53 (52.5) n rn/no: 0.0001
3 76 57 (75) o
Hormonal receptors"'
ER- 73 47 (64.38) p p/q: 0.066
ER+ 120 61 (50.83) q
PR- 85 57 (67.06) r r/s: 0.006
PR+ 108 51 (47.22) s
ER+PR+ 101 46 (45.5) NS
ER+PR- 19 15 (79) 0.012
ER-PR+ 7 5 (71.4) NS
ER-PR- 66 42 (63.6) 0.027
'Data missing in eight cases. "Data conceming infiltrating carcinomas onlY.
-Data missing in 30 cases.
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Figure 3 Histograms of the percentages of HSR+ (filled bars) and HSR-
(empty bars) tumours in relaton to the percentage of rearmanged
chromosomes. n, number of cases
chromosomes). HSRs were obsersed in 55 (49.5%7) and 74 (66%7)
of non-polyploid and polyploid tumours respectively. Thus. there
are significantly more HSR+ polyploid than non-polyploid
tumours (X'= 6.2: v = 1: P = 0.0125). A more precise analysis with
regard to HSR distribution in relation to ploidy showed that HSR-
tumours were clustered at modal chromosome number around 46
(45-49). In contrast. HSR+ tumours had a wider distribution. but
most of them were found among the most hypodiploid or hypote-
traploid tumours (Figure 2). The excess of HSR+ tumours among
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Figure 4 Percentages of overall surval in relatbon to the presence (HSR+)
or absence (HSR-) of HSRs over a 117-month period (152 patients)
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Figure 5 Percentages ofdisease-free intervals taking into account death.
ocal relapse and metastasts occurrence in relabon to the presence (HSR+)
or absence (HSR-) of HSRs over a 117-month period (152 patients)
hypodiploid (<45 chromosomes) and hypotetraploid (50-
81 chromosomes) is verv significant (X'= 17.7: * = 3: P = 0.0005:
data from Figure 2).
With regard to the correlation between the presence of HSRs
and chromosome rearrangements. HSR- tumours had a lower rate
of rearrangements than HSR+ tumours. When the tumours were
grouped according to the percentage of rearranged chromosomes
(<20%. 21-40%. 41-60%. >60%). the presence of HSRs appeared
to be strongly correlated with this percentage (X2 = 28.6: v = 3:
P = 0.0001: data from Fiaure 3). It is noteworthy that even in
tumours with few (<20%7) rearranaed chromosomes. the propor-
tion ofHSR+ tumours is not netlitible (39%).
Correlations between presence of HSRs and
clinicopathological data
Age ofthepatients
The proportion of HSR+ tumours was higher in younger than in
older patients on average (Table 2). However. comparing younger
and older patients. a significant excess of HSRs in younger
patients was observed for 55 or 60 years cut-offonly.
Tumoursize
Surprisingly. there was an inverse relationship between tumour
size and the presence of HSRs. For example. tumours below
20 mm were more frequently HSR+ than larger ones (Table 2).
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Axillarynode status
No correlations were found between the presence or absence of
metastatic axillary nodes and HSRs.
Histologicalgrade
There was a strong relationship between the presence ofHSRs and
high histological grade, the rate of HSR+ grade 3 tumours being
about threefold that ofgrade 1 (Table 2).
Steroidhormone receptorstatus
There were more HSR+ tumours among those which had low
rather than high hormone receptor expression, but the difference
reached statistical significance only for progesterone receptors
(X2= 7.6; v = 1;P = 0.006, Table 2).
Survival
The follow-up data were available for only 152 patients and ranged
from 4 to 117 months. The overall survivals were 90% and 74% at
60 months for HSR- and HSR+ tumours respectively. At 110
months, the overall survivals were 74% and 54% respectively
(Figure 4). The presence of HSRs was found to be significantly
associated with ashortenedoverall survival (X' =4; v = 1; P =0.04).
Disease-free survival
As shown in Figure 5, the presence ofHSR seems to be associated
with a shortened disease-free survival, but the difference between
HSR+ and HSR- tumours does not reach a statistical significance.
Disease-free survivals were 76% and 52% at 60 months for HSR-
and HSR+ tumours respectively. Although not statistically signifi-
cant, the presence of HSRs seemed to be related to metastatic
recurrence at 48 months, but not to local recurrence (data not
shown).
DISCUSSION
Gene amplification is a common alteration of breast cancer cells.
Molecular studies have shown that some genes, such as ERBB2,
can be amplified and overexpressed in about 30% ofthe cases, and
suggested that such amplifications could be related to prognosis
(Slamon et al, 1987; Hynes, 1993).
DNA amplification can also be detected by cytogenetic
analyses, which show that, in breast cancer, almost all amplifica-
tions are intrachromosomal and form HSRs (Gerbault-Seureau
et al, 1987). This differs from other cancers such as gliomas, in
which amplified genes are frequently extrachromosomal, forming
double minutes (Muleris etal, 1994b). HSRs, inbreast cancers, are
frequently of a large size, accounting for more than 15% of the
haploid genome per cell (Saint-Ruf et al, 1990). This suggested
that amplifications either lead to very high numbers of copies of
target DNA sequences, or that multiple sequences can be coampli-
fied. Studies by CGH (Kallioniemi et al, 1994; Muleris et al,
1994a) provided a partial answer, showing that multiple chromo-
some bands could be involved in amplification in a given tumour
with up to five different origins being detected in a single HSR
(Guan et al, 1994; Muleris et al, 1995). This raises a number of
questions about the meaning of these amplifications. Do they
occur early during tumour genesis or are they a common event
occurring during tumour progression? In the first eventuality, do
they correspond to a special mechanism influencing tumour
growth, metastatic potential and prognosis? This study was
conducted to answer these questions.
Our study showed that a proportion of HSRs occur in tumours
with minimal chromosome alterations: about40% oftumours with
less than 20% of rearranged chromosomes are HSR carriers. This
suggests that HSRs can be fonned during the early phase of
tumourdevelopment However, the strong correlation between the
presence of HSRs and the rate of rearranged chromosomes per
tumour shows that HSRs, which can occur early, are also formed
during tumourprogression. Thus, the amplification process occurs
early and continues during tumour progression. The relationship
between the presence of HSRs and age at tumour onset is of
interest. Whateverthe cut-offin relation to the age, HSR+ tumours
are always more frequent in younger than in olderpatients, but the
excess in youngerpatients reaches statistical significance at 55 and
60 years cut-off only. Among other interpretations, this could
mean that breast cancers in post-menopausal patients have a lower
tendency to form gene amplification. The effect ofageing on HSR
incidence is, however, difficult to demonstrate because ofthe low
number ofcases in each age group.
Surprisingly, the probability ofthe presence of HSR was found
to be inversely related to tumour size. Indeed. this may be also
related to age, largertumour sizes being observed in olderpatients,
but it strongly suggests that tumour progression is quite different
in young and old patients.
The strongest relationship with a pathological parameter was
found between the presence ofHSRs and high histological grade.
The presence of HSRs was also found to be related to the loss of
steroid hormone receptor expression and, in particular, to that of
progesterone receptors, the highest rate ofHSRs being observed in
ER+/PR- and ER-/PR- tumours. The presence ofHSRs appeared
to be independent ofaxillary nodal status.
It remains to be determined whether the relationship with prog-
nosis concerns the amplification process in general or is related to
the involvement of specific genes. Unfortunately, there are no
strong data to answerthis question. Interpretation ofthe prognostic
value of ERBB2 amplification is controversial (Hynes and Stem,
1994). It is now admitted that it is associated with a poorprognosis
in node-positive patients only (Noguchi et al, 1992; Marks et al,
1994). We do not know which of our HSR+ tmiou had an
ERBB2 amplification, but we expectthat ahigh proportion ofthem
had it because the incidence of ERBB2 amplification in non-
selected cases is 20-30% (Brison, 1993).
Thus, a HSR+ tumour is typically of small size and occurs in
younger patients with high histological grade disease and who are
progesterone receptor negative. As a matter offact. in our series,
86% ofthe tumours measuring 20 mm or less, PR- and ofgrade 3
were HSR+. This suggests that the presence of HSRs is related to
adverse prognostic factors. Such a conclusion is strengthened by
the data on 5-year survival, which show a lower survival for
patients with HSR+ than HSR-tunmurs.
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